The BioMed announced on the 16th that it has signed a memorandum of understanding (MOU) with Cytogen and GenomeCare to jointly develop an on-site molecular diagnostic kit for the early detection of periodontal disease, as well as a patient-tailored oral care solution platform.
Through this agreement, the three companies will collaborate on the following: ▲ development of an on-site molecular diagnostic kit for periodontal disease ▲ quantitative and qualitative analysis based on the detection of harmful bacteria in the oral cavity ▲ establishment of a personalized oral care solution platform based on diagnostic results.
The integrated platform under development aims to provide personalized oral care prescriptions to patients based on a detailed analysis of harmful bacteria distribution in the oral cavity after diagnosis at a dental clinic. It will allow for continuous monitoring of the patient’s oral microbiome. The platform will also offer valuable data that can be referenced by hospitals during the treatment of oral diseases such as periodontal disease or implant procedures. By recommending customized products according to the state of oral microorganisms, it is designed to enable more effective oral care.
The BioMed specializes in developing molecular diagnostic equipment and kits based on LabChip technology. In this joint development, the company will take the lead role, overseeing the planning and strategy for the diagnostic solution. Partner companies Cytogen and GenomeCare will collaborate by handling the entire practical development process, including the design of molecular diagnostic reagents and technical implementation.
Cytogen provides not only isolation, cultivation, and analysis of circulating tumor cells (CTCs) but also biomarker discovery and companion diagnostic services, based on its proprietary automated liquid biopsy platform for CTCs. GenomeCare possesses AI and big data-based genomic analysis technology, offering a platform for precise prediction of chromosomal abnormalities and a variety of genetic testing services.
A representative from The BioMed stated, "Periodontal disease is closely related not only to oral health issues but also to systemic diseases such as cardiovascular disease and diabetes," adding, "There are limited technologies and solutions available for early diagnosis and management." The representative continued, "Through this joint development, we aim to shift the paradigm of oral health management from a focus on diagnosis and treatment to one centered on prevention and personalized care."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
